Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial | Synapse
February 13, 2026Open Access
Sustained Efficacy of Eptinezumab in Participants with Migraine for Whom Prior Preventive Treatments Failed and Who Self-reported Psychiatric Comorbidities: Post Hoc Analysis of the Placebo-controlled DELIVER Trial
The central aim is to evaluate the sustained efficacy of eptinezumab in migraine patients with a history of treatment failure and psychiatric comorbidities.
Post hoc analysis of data from the DELIVER trial
Included participants with prior preventive treatment failures
Focused on those with self-reported psychiatric comorbidities
Eptinezumab showed sustained efficacy in reducing migraine frequency
Participants reported fewer migraine days compared to placebo
Improvement was consistent among those with psychiatric conditions